Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

mfloDx

Financiado

Cerrado

An Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistan...

An Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection Tuberculosis (TB) kills more people than any other pathogen-borne illness; yearly, 10M people fall ill and 1.6M die. TB also contributes to a growing existential crisis: the spread of antibiotic resistant bacteria. Multi-drug-resi... ver más

29/02/2024

EMPE

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

EMPE DIAGNOSTICS AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-02-29

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

EMPE

2.49M€ | Lider

BODEGAS BERONIA

696.82K€ | Participante

BODEGAS DUNVIRO S. COOP

BODEGAS OLARRA

605.35K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

mfloDx Adaptable Multiflow Diagnostic Platform to Genetically Ident... 71K€ Cerrado

Tuberculini A novel in vitro diagnostic test for drug resistant tubercul... 71K€ Cerrado

TM-REST A new platform for fast molecular detection of MDR and XDR r... 4M€ Cerrado

FAST-XDR-DETECT Development of a two approach plate system for the fast and... 4M€ Cerrado

RAPP-ID Development of RApid Point-of-Care test Platforms for Infect... 16M€ Cerrado

ResisCHIP Rapid chip-based detection of antibiotic resistances 150K€ Cerrado

Duración del proyecto: 33 meses Fecha Inicio: 2021-05-18
Fecha Fin: 2024-02-29

Líder del proyecto

EMPE DIAGNOSTICS AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Tuberculosis (TB) kills more people than any other pathogen-borne illness; yearly, 10M people fall ill and 1.6M die. TB also contributes to a growing existential crisis: the spread of antibiotic resistant bacteria. Multi-drug-resistant TB is flourishing due to incomplete diagnoses and widespread prescription of ineffective antibiotics. Commercial diagnostics often require equipment in the €12-70K range and are either very slow or incomplete. As a result, less than one-third of new TB patients undergo strain testing to determine whether antibiotic resistance is present. mfloDx is a low-cost, DNA-based TB diagnostic, similar to home-pregnancy tests. In <3 h, our test identifies nearly 100% of drug resistant TB strains with 92-97% accuracy, directly from sputum samples and with a minimum of lab equipment or training. Clinical validation is ongoing and we are preparing for in vitro diagnostic (IVD) certification for an estimated launch in late 2022. The low cost, accessibility, and stability of mfloDx tests will enable uptake in developing countries, which are the source of much antibiotic-resistant infection. EMPE‘s team are experts in TB research, business development, and diagnostic tools for infectious disease. mfloDx grew from a molecular innovation called the Padlock probe, developed by our co-founder, Mats Nilsson. EMPE CEO Pavan Asalapuram combined this technology with a lateral flow biosensor, as a fast and accurate kit to identify antibiotic resistance. EMPE has raised ~€2M in seed capital and started clinical validations with partners in Spain and India. Thus far, our facility at Karolinska Institute Science Park produces test kits for research use only (RUO). EIC funding would accelerate clinical validation of our kits toward in vitro diagnostic certification and enable the implementation of large-scale production. This project will enable us to launch our top-of-the-line product and reach a worldwide €3.5B TB diagnostics market with WHO backing.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores